S&P 500   4,585.37 (-1.50%)
DOW   34,588.06 (-1.56%)
QQQ   393.36 (-1.58%)
AAPL   163.68 (+2.15%)
MSFT   330.57 (-1.80%)
FB   326.50 (-3.41%)
GOOGL   2,850.91 (-2.05%)
AMZN   3,502.05 (-1.67%)
TSLA   1,127.92 (-0.80%)
NVDA   322.29 (-3.44%)
BABA   127.35 (-3.24%)
NIO   38.85 (-3.98%)
CGC   10.45 (-5.52%)
AMD   156.97 (-3.05%)
GE   94.86 (-3.60%)
MU   84.62 (-1.76%)
T   22.65 (-5.19%)
F   19.19 (-2.44%)
DIS   144.16 (-2.47%)
ACB   6.23 (-3.26%)
AMC   33.82 (-8.20%)
PFE   54.20 (+3.44%)
BA   194.78 (-1.87%)
S&P 500   4,585.37 (-1.50%)
DOW   34,588.06 (-1.56%)
QQQ   393.36 (-1.58%)
AAPL   163.68 (+2.15%)
MSFT   330.57 (-1.80%)
FB   326.50 (-3.41%)
GOOGL   2,850.91 (-2.05%)
AMZN   3,502.05 (-1.67%)
TSLA   1,127.92 (-0.80%)
NVDA   322.29 (-3.44%)
BABA   127.35 (-3.24%)
NIO   38.85 (-3.98%)
CGC   10.45 (-5.52%)
AMD   156.97 (-3.05%)
GE   94.86 (-3.60%)
MU   84.62 (-1.76%)
T   22.65 (-5.19%)
F   19.19 (-2.44%)
DIS   144.16 (-2.47%)
ACB   6.23 (-3.26%)
AMC   33.82 (-8.20%)
PFE   54.20 (+3.44%)
BA   194.78 (-1.87%)
S&P 500   4,585.37 (-1.50%)
DOW   34,588.06 (-1.56%)
QQQ   393.36 (-1.58%)
AAPL   163.68 (+2.15%)
MSFT   330.57 (-1.80%)
FB   326.50 (-3.41%)
GOOGL   2,850.91 (-2.05%)
AMZN   3,502.05 (-1.67%)
TSLA   1,127.92 (-0.80%)
NVDA   322.29 (-3.44%)
BABA   127.35 (-3.24%)
NIO   38.85 (-3.98%)
CGC   10.45 (-5.52%)
AMD   156.97 (-3.05%)
GE   94.86 (-3.60%)
MU   84.62 (-1.76%)
T   22.65 (-5.19%)
F   19.19 (-2.44%)
DIS   144.16 (-2.47%)
ACB   6.23 (-3.26%)
AMC   33.82 (-8.20%)
PFE   54.20 (+3.44%)
BA   194.78 (-1.87%)
S&P 500   4,585.37 (-1.50%)
DOW   34,588.06 (-1.56%)
QQQ   393.36 (-1.58%)
AAPL   163.68 (+2.15%)
MSFT   330.57 (-1.80%)
FB   326.50 (-3.41%)
GOOGL   2,850.91 (-2.05%)
AMZN   3,502.05 (-1.67%)
TSLA   1,127.92 (-0.80%)
NVDA   322.29 (-3.44%)
BABA   127.35 (-3.24%)
NIO   38.85 (-3.98%)
CGC   10.45 (-5.52%)
AMD   156.97 (-3.05%)
GE   94.86 (-3.60%)
MU   84.62 (-1.76%)
T   22.65 (-5.19%)
F   19.19 (-2.44%)
DIS   144.16 (-2.47%)
ACB   6.23 (-3.26%)
AMC   33.82 (-8.20%)
PFE   54.20 (+3.44%)
BA   194.78 (-1.87%)
NASDAQ:QLGN

Qualigen Therapeutics News Headlines

$1.43
-0.15 (-9.49%)
(As of 11/30/2021 01:25 PM ET)
Add
Compare
Today's Range
$1.34
$1.65
50-Day Range
$0.94
$2.56
52-Week Range
$0.93
$4.66
Volume
215,969 shs
Average Volume
2.47 million shs
Market Capitalization
$41.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.6

Media Mentions By Week



Qualigen Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

QLGN
News Sentiment

0.42

0.27

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

QLGN Articles
This Week

1

0

QLGN Articles
Average Week

Get Qualigen Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter.

Qualigen Therapeutics (NASDAQ:QLGN) News Headlines Today

SourceHeadline
finance.yahoo.com logoQUALIGEN THERAPEUTICS, INC. ANNOUNCES $8.82 MILLION COMMON STOCK REGISTERED DIRECT OFFERING
finance.yahoo.com - November 29 at 5:35 PM
nasdaq.com logoQualigen Therapeutics Spikes 47%, Continues Uptick
nasdaq.com - November 23 at 12:58 PM
markets.businessinsider.com logoWhy Are Qualigen Therapeutics Shares Surging During Premarket Tuesday?
markets.businessinsider.com - November 23 at 7:58 AM
nasdaq.com logoHere's Why We're A Bit Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn Situation
nasdaq.com - November 23 at 1:27 AM
benzinga.com logoQualigen Shares Spike To Session High On Volume, Now Up 5%, Following Circulation Of Zack's Small Cap Research Note Showing $9 Target On Stock
benzinga.com - November 22 at 8:24 PM
finance.yahoo.com logoQLGN: Revenues Increase 38% YoY…
finance.yahoo.com - November 22 at 8:24 PM
MarketBeat logoQualigen Therapeutics Target of Unusually Large Options Trading (NASDAQ:QLGN)
americanbankingnews.com - November 22 at 7:32 PM
finance.yahoo.com logoHere's Why Qualigen Therapeutics (NASDAQ:QLGN) Must Use Its Cash Wisely
finance.yahoo.com - November 22 at 10:22 AM
benzinga.com logoQualigen Therapeutics Q3 EPS $(0.10) Down From $0.41 YoY, Sales $1.16M Up From $1.11M YoY
benzinga.com - November 17 at 8:24 AM
MarketBeat logoQualigen Therapeutics (NASDAQ:QLGN) Posts Earnings Results
americanbankingnews.com - November 16 at 7:25 AM
finance.yahoo.com logoQualigen Therapeutics, Inc. Reports Third Quarter 2021 Financial Results
finance.yahoo.com - November 15 at 1:36 PM
finance.yahoo.com logoPeer-Reviewed Article Confirms That Qualigen’s FastPack® is as Accurate in Thyroid Stimulating Hormone Measurement -- and Much Faster -- Than a Leading Laboratory Method
finance.yahoo.com - October 19 at 9:22 AM
finance.yahoo.com logoQualigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
finance.yahoo.com - September 15 at 7:42 AM
finance.yahoo.com logoQualigen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - September 8 at 8:35 AM
finance.yahoo.com logoQLGN: Focusing on Advancement of QN-247 and RAS-F…
finance.yahoo.com - August 31 at 6:23 PM
barrons.com logoQualigen Therapeutics Inc.
barrons.com - August 18 at 5:55 AM
marketwatch.com logoQualigen Shares Slide on QN-165 Covid-19 Setback >QLGN
marketwatch.com - August 17 at 2:54 PM
finance.yahoo.com logoQualigen Therapeutics, Inc. Provides Update on Product Development Priorities and Reports Second Quarter and Six Month 2021 Financial Results
finance.yahoo.com - August 17 at 2:54 PM
finance.yahoo.com logoWhy Qualigen Therapeutics (QLGN) Stock Plunging After Q2 Update
finance.yahoo.com - August 17 at 2:54 PM
finance.yahoo.com logoQualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19
finance.yahoo.com - July 14 at 8:39 AM
finance.yahoo.com logoQLGN: On Track to File IND for QN-165 as COVID-19 Treatment in 2H21…
finance.yahoo.com - July 7 at 2:58 PM
finance.yahoo.com logoQualigen Therapeutics Announces Inclusion in Russell Microcap® Index
finance.yahoo.com - June 8 at 8:23 AM
finance.yahoo.com logoQualigen Therapeutics, Inc. to Present at the LD Micro Invitational XI Conference
finance.yahoo.com - June 2 at 11:43 AM
finance.yahoo.com logoQualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA as Chief Medical Officer
finance.yahoo.com - May 19 at 9:45 AM
finance.yahoo.com logoQualigen Therapeutics Inc to Host Earnings Call
finance.yahoo.com - May 18 at 5:23 PM
finance.yahoo.com logoQualigen Therapeutics, Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - May 14 at 5:20 PM
nasdaq.com logoWe Think Qualigen Therapeutics (NASDAQ:QLGN) Needs To Drive Business Growth Carefully
nasdaq.com - May 3 at 8:55 PM
finance.yahoo.com logoQLGN: IND Filing for QN-165 as COVID-19 Treatment Expected in 2Q21
finance.yahoo.com - April 26 at 2:02 PM
finance.yahoo.com logoQualigen Therapeutics Plans to Combat COVID-19 Variants
finance.yahoo.com - April 19 at 4:23 PM
finance.yahoo.com logoIs Qualigen Therapeutics (NASDAQ:QLGN) In A Good Position To Invest In Growth?
finance.yahoo.com - April 6 at 5:50 PM
finance.yahoo.com logoQualigen Therapeutics, Inc. to present at the Benzinga Biotech Small Cap Conference
finance.yahoo.com - March 18 at 9:18 AM
finance.yahoo.com logoQualigen Therapeutics, Inc. Promotes Shishir Sinha to Chief Operating Officer Position
finance.yahoo.com - March 9 at 1:36 PM
finance.yahoo.com logoQualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference
finance.yahoo.com - March 8 at 12:07 PM
finanznachrichten.de logoQualigen Therapeutics, Inc.: Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL
finanznachrichten.de - March 1 at 11:52 AM
finance.yahoo.com logoQualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL
finance.yahoo.com - March 1 at 11:52 AM
marketwatch.com logoBest Penny Stocks To Buy Before Friday? 4 Under $4 To Watch
marketwatch.com - February 25 at 12:40 AM
benzinga.com logoQualigen Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference
benzinga.com - January 5 at 3:07 PM
benzinga.com logoInsider Buys Qualigen Therapeutics Stock
benzinga.com - December 30 at 1:40 PM
finance.yahoo.com logoQualigen Therapeutics Issues CEO Letter to Stockholders with 2021 Outlook
finance.yahoo.com - December 22 at 1:01 PM
finance.yahoo.com logoQualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering
finance.yahoo.com - December 18 at 6:41 PM
finance.yahoo.com logoQualigen Therapeutics, Inc. Announces $12 Million Registered Direct Offering
finance.yahoo.com - December 16 at 12:10 PM
finance.yahoo.com logoQualigen Therapeutics Announces Issuance of U.S. Patent for Expanded Applications of ALAN Anticancer Platform Technology
finance.yahoo.com - December 15 at 10:46 AM
finance.yahoo.com logoQualigen Therapeutics Announces Board Member Amy Broidrick as EVP, Chief Strategy Officer and Names Sidney Emery, Jr. to its Board
finance.yahoo.com - December 8 at 10:49 AM
finance.yahoo.com logoQualigen Therapeutics Completes Recertification of Existing AS1411 Drug Supply for Use in Upcoming Clinical Trials
finance.yahoo.com - December 2 at 9:24 AM
finance.yahoo.com logoQLGN: Testing AS1411 as COVID-19 Treatment…
finance.yahoo.com - November 30 at 9:40 PM
seekingalpha.com logoQualigen Therapeutics EPS misses by $0.61, misses on revenue
seekingalpha.com - November 14 at 7:17 PM
finance.yahoo.com logoQualigen Therapeutics Issues CEO Letter to Stockholders, Reports on Significant Progress and Fiscal Second Quarter Financial Results
finance.yahoo.com - November 13 at 1:13 PM
finance.yahoo.com logoQualigen Therapeutics Engages STA Pharmaceutical as GMP Manufacturer of AS1411 for Clinical Trials
finance.yahoo.com - November 5 at 12:36 PM
nasdaq.com logoQualigen Therapeutics, Inc. Common Stock (QLGN)
nasdaq.com - November 3 at 10:42 PM
finance.yahoo.com logoQualigen Therapeutics, Inc. (QLGN)
finance.yahoo.com - November 1 at 1:00 PM
Get Qualigen Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.